Nama's AI scorecard currently rates IDEXX Laboratories Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is IDXX's P/E ratio?

IDEXX Laboratories trades at a trailing price-to-earnings ratio of 45.6.

When does IDXX report earnings?

IDEXX Laboratories's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $3.71.

What is the IDXX price target?

The median analyst price target from 12 analysts is $707.50, with a range of $470.00 – $810.00.

Is IDXX Shariah compliant?

Nama's AAOIFI-style screen reads IDEXX Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

IDEXX Laboratories (IDXX)

Healthcare · Diagnostics Research · NASDAQ

S&P 500Nasdaq-100

IDEXX Laboratories (IDXX) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $53.26B, a trailing price-to-earnings ratio of 45.6 and a free-cash-flow yield of 1.9%. Over the most recent reported fiscal year, revenue grew 10.4% and free cash flow per share grew 34.4%. Nama's AI scorecard rates it Buy, 7.8 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 7.8/10

Clearly positive, short of the top band. As of Nov 7, 2026.

Momentum

Trailing · -29.0% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-12.2%

How far the last close sits under the highest price of the past five years.

Market cap	$53.26B
Trailing P/E	45.6
Price / book	33.1
Price / sales	11.7
FCF yield	1.9%
Dividend yield	—
Gross margin	62.5%
Operating margin	32.0%
Net margin	25.0%
Revenue growth (YoY)	+10.4%
Revenue growth (3-yr annual)	+8.5%
EPS growth (YoY)	+16.2%
FCF/share growth (YoY)	+34.4%
Beta	1.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

IDXX earnings

Next report: Feb 1, 2027 (Q4 2026, EPS estimate $3.71). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 2, 2026	$4.01	$3.71	+8.1%	$1.21B
Q2 2026	Aug 4, 2026	$4.27	$3.93	+8.7%	$1.22B
Q1 2026	May 5, 2026	$3.47	$3.41	+1.8%	$1.14B
Q4 2025	Feb 2, 2026	$3.08	$2.94	+4.8%	$1.09B

IDXX analyst price target

Median target $707.50 from 12 analysts, ranging $470.00 – $810.00.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2
ILMN	Illumina	$32.23B	40.6

Explore live IDXX data on Nama Insights →

Recent Congressional trades

IDEXX Laboratories trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
April McClain Delaney	House	Sell	$1,001 - $15,000	Feb 2, 2026
April McClain Delaney	House	Sell	$1,001 - $15,000	Nov 4, 2025
Byron Donalds	House	Buy	$1,001 - $15,000	Oct 7, 2025
Byron Donalds	House	Buy	$1,001 - $15,000	Oct 7, 2025
April McClain Delaney	House	Sell	$1,001 - $15,000	Sep 2, 2025
April McClain Delaney	House	Sell	$1,001 - $15,000	Aug 5, 2025
Jefferson Shreve	House	Sell	$100,001 - $250,000	Jun 22, 2025
Rob Bresnahan	House	Buy	$1,001 - $15,000	Jun 9, 2025
Jefferson Shreve	House	Buy	$50,001 - $100,000	May 8, 2025
April McClain Delaney	House	Buy	$1,001 - $15,000	May 2, 2025
April McClain Delaney	House	Buy	$1,001 - $15,000	May 2, 2025
April McClain Delaney	House	Buy	$1,001 - $15,000	May 2, 2025

IDXX FAQ

Is IDXX a buy?: Nama's AI scorecard currently rates IDEXX Laboratories Buy (7.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is IDXX's P/E ratio?: IDEXX Laboratories trades at a trailing price-to-earnings ratio of 45.6.
When does IDXX report earnings?: IDEXX Laboratories's next scheduled report is on Feb 1, 2027. Analysts expect EPS of $3.71.
What is the IDXX price target?: The median analyst price target from 12 analysts is $707.50, with a range of $470.00 – $810.00.
Is IDXX Shariah compliant?: Nama's AAOIFI-style screen reads IDEXX Laboratories as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.